Agios Pharmaceuticals: Q3 Earnings Insights

 

Shares of Agios Pharmaceuticals AGIO were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share were up 20.99% over the past year to ($1.43), which missed the estimate of ($1.38).

Revenue of $34,706,000 higher by 33.36% year over year, which missed the estimate of $38,020,000.

Looking Ahead

Agios Pharmaceuticals hasn't issued any earnings guidance for the time being.

Agios Pharmaceuticals hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Nov 05, 2020

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/wf6ni9pt

Recent Stock Performance

52-week high: $56.74

52-week low: $27.77

Price action over last quarter: down 8.38%

Company Profile

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

AGIO Logo
AGIOAgios Pharmaceuticals Inc
$34.05-1.30%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
18.71
Growth
Not Available
Quality
Not Available
Value
7.40
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Comments
Loading...